Guggenheim Maintains Buy on Insmed, Lowers Price Target to $205

Benzinga Newsdesk www.benzinga.com Negative 65.6%

Neg 65.6% Neu 0% Pos 0%

Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $207 to $205.

Comments

No comments yet. Be the first!